Press Releases

GW and Bayer Extend Marketing Agreement For Sativex to Canadian Market

6 November 2003

GW Pharmaceuticals plc (“GW”) and Bayer Healthcare AG (“Bayer”) announce that they have extended their marketing agreement for Sativex®, GW’s cannabis-based medicinal extract product, to the Canadian ... more

GW Raises £20 Million to Accelerate Development Programme

27 June 2003

GW is pleased to announce that it is raising approximately £20 million before expenses through a placing for cash of 9,904,395 new GW ordinary shares at 200 pence per share.... more

GW and Bayer Announce Marketing Agreement on Pioneering New Cannabis-based Treatment

21 May 2003

GW Pharmaceuticals plc (“GW”) and Bayer AG (“Bayer”) have entered into an exclusive marketing agreement for GW’s cannabis-based medicinal extract product, to be marketed under the Sativex® brand name.... more

Appointment of Non-Executive Director

16 April 2003

GW announces the appointment of Hans Schram as a non-executive director with immediate effect. Mr Schram has over 20 years experience in global pharmaceutical business development and marketing.... more

GW Pharmaceuticals plc enhances cannabinoid research activities, appoints Professor Roger Pertwee as Director of Pharmacology

12 March 2003

GW Pharmaceuticals plc, the company developing a portfolio of non-smoked cannabis-based prescription medicines, announces that Professor Roger Pertwee, Professor of Neuropharmacology at the University... more

Submission of Regulatory Application to MCA

4 March 2003

GW announces that the regulatory dossier for the Company’s first cannabis-based prescription medicine has been submitted to the UK Medicines Control Agency as planned.... more

Response to Media Comment

3 February 2003

GW notes recent media comments relating to its commercialisation discussions. The Company has consistently stated its commercial strategy to be to enter into partnerships following Phase III trial res... more

GW to develop new Cannabinoid Opportunities with Professor Raphael Mechoulam

21 January 2003

GW Pharmaceuticals plc, the company developing a portfolio of non-smoked, cannabis-based prescription medicines, has established an extensive research collaboration with Professor Raphael Mechoulam, f... more

Preliminary Results for the Year Ended 30 September 2002

15 January 2003

GW Pharmaceuticals plc, the company licensed by the UK Home Office to work with cannabis and a range of controlled drugs for medical research purposes, announces its preliminary results for the year e... more